Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 20 04:00PM ET
4.84
Dollar change
+1.31
Percentage change
37.11
%
Index- P/E- EPS (ttm)-2.88 Insider Own43.68% Shs Outstand30.25M Perf Week16.91%
Market Cap229.36M Forward P/E- EPS next Y-0.91 Insider Trans0.00% Shs Float19.47M Perf Month10.50%
Income-60.42M PEG- EPS next Q-0.24 Inst Own32.57% Short Float0.54% Perf Quarter25.71%
Sales24.78M P/S9.26 EPS this Y20.04% Inst Trans344.45% Short Ratio2.83 Perf Half Y23.79%
Book/sh-1.16 P/B- EPS next Y50.14% ROA-117.51% Short Interest0.11M Perf Year144.44%
Cash/sh0.54 P/C8.91 EPS next 5Y- ROE- 52W Range1.86 - 5.24 Perf YTD124.07%
Dividend Est.- P/FCF- EPS past 5Y-17.26% ROI- 52W High-7.63% Beta0.91
Dividend TTM- Quick Ratio0.85 Sales past 5Y-5.10% Gross Margin42.40% 52W Low160.22% ATR (14)0.44
Dividend Ex-Date- Current Ratio0.94 EPS Y/Y TTM-19.76% Oper. Margin-97.89% RSI (14)61.53 Volatility14.75% 11.29%
Employees54 Debt/Eq- Sales Y/Y TTM-41.19% Profit Margin-243.82% Recom1.00 Target Price9.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q42.23% Payout- Rel Volume4.50 Prev Close3.53
Sales Surprise-10.27% EPS Surprise-56.25% Sales Q/Q-3.35% EarningsNov 14 AMC Avg Volume37.23K Price4.84
SMA2014.91% SMA5025.28% SMA20033.22% Trades Volume167,576 Change37.11%
Date Action Analyst Rating Change Price Target Change
Nov-02-20Initiated Truist Buy $20
Nov-02-20Initiated Piper Sandler Overweight $20
Nov-02-20Initiated Cowen Outperform $20
Nov-02-20Initiated Cantor Fitzgerald Overweight $20
Dec-02-24 08:00AM
Nov-14-24 04:05PM
Nov-13-24 04:05PM
07:27AM
Oct-29-24 04:05PM
04:05PM Loading…
Oct-23-24 04:05PM
Oct-17-24 04:15PM
Oct-15-24 11:01AM
Sep-18-24 08:00AM
Sep-06-24 04:23PM
Sep-05-24 04:05PM
Sep-03-24 04:05PM
Aug-21-24 07:00AM
Aug-20-24 07:00AM
Aug-07-24 04:05PM
04:05PM Loading…
Aug-01-24 04:05PM
Jul-31-24 04:05PM
Jul-30-24 04:05PM
Jul-17-24 04:15PM
07:00AM
Jul-16-24 07:00AM
Jul-11-24 04:05PM
03:24PM
Jun-17-24 08:01AM
08:00AM
May-13-24 08:00AM
May-09-24 10:55PM
04:05PM
May-02-24 04:05PM
Apr-29-24 09:00AM
04:05PM Loading…
Apr-24-24 04:05PM
Mar-07-24 09:53PM
04:05PM
Feb-22-24 04:05PM
Feb-20-24 10:37AM
Jan-10-24 04:05PM
Dec-18-23 08:00AM
Nov-13-23 04:05PM
Nov-09-23 08:30AM
Nov-06-23 04:05PM
Oct-18-23 08:00AM
Sep-20-23 08:30AM
Sep-19-23 08:36AM
Sep-18-23 04:08PM
Sep-08-23 08:30AM
Sep-06-23 04:05PM
Aug-30-23 08:30AM
Aug-21-23 09:42AM
Aug-15-23 05:21AM
Aug-14-23 04:05PM
Jul-31-23 04:05PM
Jul-26-23 03:29PM
Jul-17-23 04:05PM
Jul-13-23 04:30PM
May-19-23 01:45PM
08:15AM
May-13-23 08:17AM
May-11-23 09:58AM
05:51AM
May-10-23 04:05PM
May-03-23 04:05PM
10:42AM
Apr-20-23 04:30PM
Apr-17-23 06:11AM
Apr-05-23 09:55AM
Mar-27-23 06:26AM
Mar-23-23 06:08AM
Mar-22-23 04:01PM
08:30AM
Mar-20-23 12:01PM
08:00AM
Mar-15-23 04:05PM
Feb-27-23 08:15AM
Jan-31-23 08:00AM
Jan-26-23 12:00PM
09:40AM
Jan-21-23 09:58AM
Jan-09-23 08:15AM
Dec-15-22 08:00AM
Dec-10-22 07:38AM
Dec-01-22 09:04AM
Nov-30-22 04:08PM
Nov-21-22 04:05PM
Nov-16-22 06:00AM
Nov-14-22 05:25PM
04:01PM
Nov-07-22 04:05PM
07:40AM
Oct-25-22 09:47AM
Oct-24-22 08:00AM
Oct-18-22 04:05PM
Oct-11-22 04:35PM
07:44AM
Aug-26-22 09:00AM
Aug-17-22 04:05PM
Aug-16-22 01:53PM
Aug-14-22 10:16AM
Aug-11-22 04:05PM
03:09PM
Aug-10-22 06:56PM
Elutia, Inc. operates as a biotechnology company. It develops biologic products to improve compatibility between medical devices and the patients who need them. The firm operates through the following segments: Device Protection, Women's Health, Orthobiologics and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women's Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Orthobiologics segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Silver Spring, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ferguson MatthewCHIEF FINANCIAL OFFICERJul 31 '24Option Exercise1.43105,080150,002257,823Jul 31 05:00 PM
Ferguson MatthewCHIEF FINANCIAL OFFICERMar 08 '24Option Exercise0.001,2880121,807Mar 14 04:43 PM